Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 17
---
 per warrant, (2) 110,675,600 Ordinary Shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series
D warrants, or Series D Warrants at an exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary
Shares issuable upon the exercise of warrants issued to the placement agent in the offering at an exercise price of $375.00 per warrant,
or May 2023 Placement Agent Warrants.

On June 14, 2023, we held our June AGM, and our
shareholders passed resolutions, among other procedural items, to approve the allotment of, and disapplication of pre-emption rights in
respect of, up to 7.0 billion Ordinary Shares. On June 14, 2023, we also held a June GM, and our shareholders passed resolutions to, among
other things, (i) re-designate our deferred shares into A Deferred Shares, and (ii) subdivide our Ordinary Shares of £0.02 nominal
value each into one Ordinary Share of £0.001 nominal value and 19 B Deferred Shares of £0.001 nominal value each.

On
June 20, 2023, we issued the Series C Warrants, Series D Warrants and May 2023 Placement Agent Warrants after receiving required shareholder
approval of the allotment of, and disapplication of pre-emption rights with respect to the Ordinary Shares to be issued under the warrants
at our June GM.

Between
June 20, 2023, and December 31, 2024, we have issued 166,017,700 ordinary shares upon the exercise of Series C Warrants issued in the
May 2023 registered direct offering.

On
July 5, 2023, we effected a ratio change to the Depositary Shares, pursuant to which the ratio of ordinary shares to Depositary Shares
was changed such that one Depositary Share represented 400 ordinary shares. Our ordinary shares were not affected by this change and no
fractional Depositary Shares were issued.

On November 22, 2023, we entered into a series of agreements with (1) Adhera Therapeutics, Inc. and certain of its secured noteholders, or the Secured Noteholders, and (1) Melior Pharmaceuticals I, Inc., or Melior. On December 21, 2023, in connection with